The Impact of Biomarkers and Modern Disease-Modifying Therapies in MS

Author(s):

Gabriel Pardo, MD, FAAN,Martin Belkin, DO

Panelists discuss how modern multiple sclerosis (MS) management has evolved from symptomatic treatment to a proactive, personalized approach leveraging advanced biomarkers and sophisticated disease-modifying therapies. The focus has shifted toward early intervention, precise monitoring, and comprehensive disease control, significantly improving patient outcomes and quality of life.

Now Viewing

EP: 1.The Impact of Biomarkers and Modern Disease-Modifying Therapies in MS

EP: 2.Understanding PIRA in MS: Key Insights and Advances From ECTRIMS 2024

EP: 3.Biomarkers and Therapeutic Impact on PIRA

EP: 4.Disability Accumulation and Early Therapy: Insights from MAGNIFY-MS and High-Efficacy DMT Data

EP: 5.Addressing PIRA in Clinical Practice and Patient Conversations

EP: 6.Exploring DMTs: Blood-Brain Barrier Penetration and Cognitive Health Benefits

EP: 7.Long-Term Cognitive Effects of Cladribine: SDMT Score Changes in the CLARIFY-MS Extension Study

EP: 8.Evaluating Cognitive Health: Tools, Markers, and the Concept of Cognitive PIRA

EP: 9.Managing Disease Progression in MS: Changing Treatments and Clinician Advice

Video content above is prompted by the following:

Please share how your management of MS has changed in recent years with the availability of biomarkers and highly efficacious disease-modifying therapies.